Risk factors and therapeutic response in Chinese patients with peptic ulcer disease

Table 2 The impact of therapeutic efficacy according to H. pylori infection and ulcer location of patients n (%)

	Therapeutic efficacy		Total	P-value
	Ulcer healed	Ulcer unhealed
H. pylori
GU
Positive infections	77 (70.6)	32 (29.4)	109	0.661
Negative infections	99 (68.3)	46 (31.7)	145
DU
Positive infections	87 (71.9)	34 (28.1)	121	0.505
Negative infections	55 (75.3)	18 (24.7)	73
Medications
GU
Treat with PPI	131 (79.4)	34 (20.6)	165	0.007
Treat with H2RA	56 (62.9)	33 (37.1)	89
DU
Treat with PPI	115 (78.2)	32 (21.8)	147	0.430
Treat with H2RA	34 (72.3)	13 (27.7)	47

All analyzed with Pearson’s χ² test. GU: Gastric ulcer; DU: Duodenal ulcer; PPI: Proton-pump inhibitor; H2RA: H2-receptor antagonist.